News

Hāwera Hospital Permanent, part-time or full-time role Play a pivotal role in rural health Health New Zealand | Te Whatu Ora is firmly grounded in the principles of Te Tiriti o Waitangi and is committed to building a health system that serves all New Zealanders. About the role Mātanga tapuhi nurse practitioners have advanced education, clinical training and the demonstrated competence and legal authority to practise beyond the level of a registered nurse. In this role, you will: work...

We are writing to inform you of the following: Discontinuation: Ipratropium bromide nebuliser soln, 250 mcg per ml, 2 ml ampoule (Univent) New listing: Ipratropium bromide nebuliser soln, 0.5mg per 2ml ampoule (Viatris) Ipratropium bromide nebuliser soln, 250 mcg per ml, 2 ml ampoule (Univent) has been discontinued. Remaining Univent stock is being reserved for ambulances. The alternate Section 29 Accord brand currently listed is expected to be depleted by May 2026.   A second alternate,...

Pharmac has decided to fund two new combination treatments and widen access to ibrutinib for people with chronic lymphocytic leukaemia (CLL) from 1 May 2026.Under this decision: People with CLL will be able to receive venetoclax with ibrutinib or venetoclax with obinutuzumab as first‑line treatments, meaning they can be used as an initial treatment option rather than after other treatments have been tried. Access to ibrutinib will be widened so it can be used on its own as a second line...

I hope you were all able to take a moment to rest and recharge over the long weekend. The start of the year has been a busy one, and I want to acknowledge the work you do every day to support people, families, whānau and communities, and the impact it can have on your own wellbeing.   Today marks an important milestone. We have launched public consultation on the draft Mental Health and Wellbeing Strategy – a ten-year plan to guide our collective efforts to improve mental health and wellbeing...

Pharmac has decided to fund letermovir, a medicine that helps prevent serious viral infection in people with very weak immune systems. From 1 May 2026, letermovir will be funded for people who have had a stem cell transplant, as well as a small number of other people with severe immunosuppression who cannot use other funded antiviral medicines. This decision follows public consultation and strong feedback from clinicians involved in stem cell transplant care, patient groups, and Pharmac’s...

Our latest webinars and podcast for you:  Whole of life protection: A focus on adult vaccination WEBINAR 14 April: Nikki Turner on the importance of adult immunisation as part of comprehensive preventive care in primary practice.  Register here   Redefining insomnia management WEBINAR 21 April: David Cunnington, a specialist sleep physician, will review contemporary insomnia management, including CBT-I, and discuss the role of medications, including lemborexant, a newer agent.  Register here...